At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 154 enrolled
Drug / intervention
Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV +2 morebiological
Likely dose
Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV 0.25mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
In the news
1 article- Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026GlobeNewswire Biotech·2026-06-14press release
Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.
Exploratory Clinical Study of MT-2301 in Healthy Infants (Phase 2)
In Brief
A Phase 2 clinical trial evaluating Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV, Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV, and 1 other intervention for Haemophilus Influenza Type b. Completed, enrolled 154 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered with DPT-IPV using ActHIB® as a control in healthy infants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHaemophilus Influenza Type b
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedMay 2014
Primary CompletionJan 2015
Study CompletionSep 2015
TodayJul 2026
First PostedMay 16, 2014
Enrollment StartApr 1, 2014
Primary CompletionJan 1, 2015
Study CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.1 years ago
Interventions
Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPVbiological
0.25mL, subcutaneous injection
Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPVbiological
0.5mL, subcutaneous injection
Haemophilus influenza type b conjugate vaccine + DPT-IPVbiological
0.5mL, subcutaneous injection